RT Journal Article
SR Electronic
T1 Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.05.21259918
DO 10.1101/2021.07.05.21259918
A1 Dan H. Barouch
A1 Kathryn E. Stephenson
A1 Jerald Sadoff
A1 Jingyou Yu
A1 Aiquan Chang
A1 Makda Gebre
A1 Katherine McMahan
A1 Jinyan Liu
A1 Abishek Chandrashekar
A1 Shivani Patel
A1 Mathieu Le Gars
A1 Anne Marit de Groot
A1 Dirk Heerwegh
A1 Frank Struyf
A1 Macaya Douoguih
A1 Johan van Hoof
A1 Hanneke Schuitemaker
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.05.21259918.abstract
AB Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported1-3. We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5×1010 vp or 1011 vp Ad26.COV2.S and in 5 participants who received placebo2. We evaluated antibody and T cell responses on day 239, which was 8 months after the single-shot vaccine regimen (N=10) or 6 months after the two-shot vaccine regimen (N=10), although the present study was not powered to compare these regimens3. We also report neutralizing antibody responses against the parental SARS-CoV-2 WA1/2020 strain as well as against the SARS-CoV-2 variants D614G, B.1.1.7 (alpha), B.1.617.1 (kappa), B.1.617.2 (delta), P.1 (gamma), B.1.429 (epsilon), and B.1.351 (beta).Competing Interest StatementD.H.B. is a co-inventor on related vaccine patents. J.S., M.L.G., A.M.G., D.H., F.S., M.D., J.V.H., and H.S. are employees of Janssen Pharmaceuticals and may be co-inventors on related vaccine patents.Clinical TrialNCT04436276Funding StatementWe acknowledge support from Janssen Vaccines & Prevention BV, the Ragon Institute of MGH, MIT, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the Musk Foundation, the National Institutes of Health (CA260476). This project has been funded in part with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:BIDMC IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for access to the study data can be submitted to D.H.B. (dbarouch{at}bidmc.harvard.edu).